Prognostic and Clinical Value of Interleukin 6 and CD45
Adult
Aged
Aged, 80 and over
Ascitic Fluid
/ metabolism
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ metabolism
Female
Humans
Inflammation
/ diagnosis
Interleukin-6
/ metabolism
Leukocyte Common Antigens
/ metabolism
Leukocytes, Mononuclear
/ immunology
Lipopolysaccharide Receptors
/ metabolism
Middle Aged
Neoplasm Staging
Ovarian Neoplasms
/ diagnosis
Prognosis
Programmed Cell Death 1 Ligand 2 Protein
/ metabolism
Survival Analysis
Young Adult
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
07
2020
revised:
26
08
2020
accepted:
11
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
13
7
2021
Statut:
epublish
Résumé
Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiation between malignant and benign tumors, monitoring the progression of the disease, and identification of patients that will respond to implemented treatment. Our study is aimed at evaluating the profile of IL-6 in the plasma and peritoneal fluid (PF) of patients with various clinical manifestations of OC (
Identifiants
pubmed: 33062717
doi: 10.1155/2020/1715064
pmc: PMC7545411
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Interleukin-6
0
Lipopolysaccharide Receptors
0
PDCD1LG2 protein, human
0
Programmed Cell Death 1 Ligand 2 Protein
0
Leukocyte Common Antigens
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1715064Informations de copyright
Copyright © 2020 Iwona Wertel et al.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Gynecol Oncol. 2016 Jul;142(1):184-189
pubmed: 27063803
Clin Cancer Res. 2017 Jul 1;23(13):3453-3460
pubmed: 27986748
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518684
Sci Rep. 2020 Feb 10;10(1):2213
pubmed: 32042020
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
Cancer Immunol Res. 2018 Oct;6(10):1260-1273
pubmed: 30012633
Gynecol Oncol. 2006 Dec;103(3):793-6
pubmed: 17023036
Cytokine. 1995 Aug;7(6):542-7
pubmed: 8580370
Gynecol Oncol. 2015 Aug;138(2):352-7
pubmed: 26001328
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cancer Treat Rev. 2012 Nov;38(7):904-10
pubmed: 22651903
Front Immunol. 2020 Mar 24;11:487
pubmed: 32265932
Int J Biol Markers. 2007 Jul-Sep;22(3):172-80
pubmed: 17922459
Oncol Lett. 2018 May;15(5):6457-6468
pubmed: 29616115
Clin Chim Acta. 2018 Jul;482:27-32
pubmed: 29572186
Cancer Res. 2013 Dec 1;73(23):6900-12
pubmed: 23975756
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Tumour Biol. 2016 Apr;37(4):5031-7
pubmed: 26541760
Drugs Today (Barc). 2006 Sep;42(9):559-76
pubmed: 17028666
Mol Oncol. 2020 Jun;14(6):1381-1396
pubmed: 32174012
Onco Targets Ther. 2015 Feb 23;8:471-85
pubmed: 25750541
Anticancer Res. 2009 Aug;29(8):2875-84
pubmed: 19661290
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Cancers (Basel). 2019 Aug 26;11(9):
pubmed: 31455033
J Clin Invest. 2018 Apr 2;128(4):1708
pubmed: 29608143
Gynecol Oncol. 2017 Mar;144(3):607-612
pubmed: 28065619
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
J Natl Cancer Inst. 2002 Apr 17;94(8):617-29
pubmed: 11959895
BMC Cancer. 2015 Jul 01;15:492
pubmed: 26122176
BMC Cancer. 2011 May 30;11:210
pubmed: 21619709
Cancer Manag Res. 2019 Jul 23;11:6815-6827
pubmed: 31440080
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Clin Cancer Res. 2011 Sep 15;17(18):6083-96
pubmed: 21795409
PLoS One. 2017 Apr 28;12(4):e0176822
pubmed: 28453554
Arthritis Res Ther. 2006;8 Suppl 2:S4
pubmed: 16899108
PLoS One. 2012;7(12):e50946
pubmed: 23284651
J Cancer. 2019 Jul 23;10(19):4463-4472
pubmed: 31528210
Cancer Res. 2005 Dec 1;65(23):10794-800
pubmed: 16322225
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Transl Lung Cancer Res. 2015 Feb;4(1):55-66
pubmed: 25806346
Int J Gynecol Pathol. 2000 Jan;19(1):7-15
pubmed: 10638449
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Anticancer Res. 1997 Jan-Feb;17(1A):337-42
pubmed: 9066674
J Obstet Gynaecol. 2020 Apr;40(3):401-405
pubmed: 31476946
Immunol Invest. 2020 Jul;49(5):510-521
pubmed: 31755326
Oncotarget. 2016 Dec 13;7(50):83148-83159
pubmed: 27825119
Arch Biochem Biophys. 2020 May 15;684:108334
pubmed: 32173334
Scand J Immunol. 2006 May;63(5):321-9
pubmed: 16640655
PLoS One. 2018 Mar 26;13(3):e0194993
pubmed: 29579127
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
J Ovarian Res. 2019 Jul 23;12(1):68
pubmed: 31337420
Hum Pathol. 2018 Apr;74:135-147
pubmed: 29288043
Oncotarget. 2018 Apr 27;9(32):22832-22849
pubmed: 29854318
Cytokine. 2015 May;73(1):108-13
pubmed: 25743245
J Mol Med (Berl). 2013 Mar;91(3):357-68
pubmed: 23052480
J Pathol. 2020 Apr;250(5):573-592
pubmed: 32086811
Arthritis Res Ther. 2006;8 Suppl 2:S2
pubmed: 16899106
J Oncol. 2020 Feb 21;2020:8797683
pubmed: 32148497